Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Operations: 2012-2025

Historic Cash from Operations for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to -$88.2 million.

  • Agios Pharmaceuticals' Cash from Operations fell 4.67% to -$88.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$409.9 million, marking a year-over-year decrease of 24.54%. This contributed to the annual value of -$389.8 million for FY2024, which is 31.68% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Cash from Operations stood at -$88.2 million for Q3 2025, which was down 14.30% from -$77.1 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Cash from Operations' 5-year high stood at -$61.6 million during Q3 2023, with a 5-year trough of -$133.2 million in Q4 2024.
  • For the 3-year period, Agios Pharmaceuticals' Cash from Operations averaged around -$87.5 million, with its median value being -$84.2 million (2024).
  • In the last 5 years, Agios Pharmaceuticals' Cash from Operations surged by 36.72% in 2022 and then slumped by 83.71% in 2024.
  • Agios Pharmaceuticals' Cash from Operations (Quarterly) stood at -$84.1 million in 2021, then rose by 21.32% to -$66.2 million in 2022, then dropped by 9.56% to -$72.5 million in 2023, then crashed by 83.71% to -$133.2 million in 2024, then dropped by 4.67% to -$88.2 million in 2025.
  • Its Cash from Operations was -$88.2 million in Q3 2025, compared to -$77.1 million in Q2 2025 and -$111.5 million in Q1 2025.